NCT06503848

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 108 (estimated)
• Sponsor: Hospital Universitari Vall d'Hebron Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.

Detailed description

There is still an unmet need in acute migraine treatment, some patients don't respond properly to acute medication. There are some interindividual differences in clinical characteristics of migraine attacks. These differences may determine the response to acute treatment. Describing the phenotypical differences between patients who are responders and patients non-responders will allow us to offer a personalized treatment. The aim of the study is to determine which characteristics are associated with a response or a non-response to acute treatment with sumatriptan. Participants will be asked to register the headache characteristics and accompanying symptoms during 4 spontaneous migraine attacks and its response to treatment with sumatriptan.

Conditions

• Migraine Disorders

Interventions

Type	Name	Description
DRUG	Sumatriptan	Register the response to treatment and headache characteristics.

Timeline

• Start date: 2024-01-25
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2024-07-16
• Last updated: 2024-10-28

Locations

1 site across 1 country: Spain